Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirteen ratings firms that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $185.20.

RGEN has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday. They set a "hold" rating and a $165.00 price target for the company. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective on the stock. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday. They issued a "hold" rating and a $165.00 price target for the company.

Institutional Trading of Repligen

Hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. boosted its stake in Repligen by 937.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 30,189 shares of the biotechnology company's stock worth $3,806,000 after purchasing an additional 27,280 shares in the last quarter. Raymond James & Associates grew its holdings in shares of Repligen by 3.7% during the second quarter. Raymond James & Associates now owns 55,119 shares of the biotechnology company's stock valued at $6,948,000 after buying an additional 1,951 shares during the last quarter. Fifth Third Bancorp increased its position in shares of Repligen by 6.4% during the second quarter. Fifth Third Bancorp now owns 3,096 shares of the biotechnology company's stock valued at $390,000 after acquiring an additional 187 shares in the last quarter. Fifth Third Wealth Advisors LLC purchased a new position in Repligen in the 2nd quarter worth approximately $273,000. Finally, Slow Capital Inc. lifted its position in Repligen by 10.7% in the 2nd quarter. Slow Capital Inc. now owns 16,165 shares of the biotechnology company's stock valued at $2,038,000 after acquiring an additional 1,558 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Trading Down 6.8 %

Shares of RGEN stock traded down $10.80 on Wednesday, hitting $147.34. 573,665 shares of the company's stock traded hands, compared to its average volume of 655,454. The stock has a market capitalization of $8.26 billion, a price-to-earnings ratio of -398.21, a P/E/G ratio of 4.64 and a beta of 0.96. The company's fifty day simple moving average is $143.61 and its 200 day simple moving average is $141.74. Repligen has a one year low of $113.50 and a one year high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. During the same period last year, the firm earned $0.23 earnings per share. The company's revenue for the quarter was up 9.7% compared to the same quarter last year. Equities analysts forecast that Repligen will post 1.54 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.